Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Helus Pharma ( (HELP) ) has shared an announcement.
On April 27, 2026, Helus Pharma announced a collaboration with mental health organization TARA Mind, which works closely with Veterans Exploring Treatment Solutions, to support recruitment into its PARADIGM HLP003 Phase 3 program for major depressive disorder and expand mental health outreach to U.S. veterans. The partnership is positioned as directly aligned with President Trump’s April 18, 2026 executive order on accelerating treatments for serious mental illness, signaling Helus Pharma’s intent to deepen its presence in veteran mental health, bolster enrollment for its FDA Breakthrough Therapy-designated HLP003, and reinforce its patient-centric reputation in a high-need segment of the psychiatric drug market.
TARA Mind and VETS will use their veteran-focused networks and collaborative care platform to raise awareness of clinical research opportunities and connect veterans to Helus Pharma’s ongoing Phase 3 trial, potentially improving trial diversity and real-world relevance for stakeholders. By tying its clinical program to national policy priorities around veteran suicide, PTSD and depression, Helus Pharma aims to differentiate its NSA pipeline in a competitive mental health landscape and signal to investors and partners that it is pursuing both regulatory momentum and social impact in one of the most scrutinized areas of U.S. healthcare.
The most recent analyst rating on (HELP) stock is a Buy with a $95.00 price target. To see the full list of analyst forecasts on Helus Pharma stock, see the HELP Stock Forecast page.
More about Helus Pharma
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs) designed to activate serotonin pathways and promote neuroplasticity for patients with depression, anxiety and other mental health conditions. Its lead candidate HLP003 is in Phase 3 development for adjunctive treatment of major depressive disorder with U.S. FDA Breakthrough Therapy designation, while HLP004 is in Phase 2 for generalized anxiety disorder, supported by an extensive NSA research portfolio across operations in Canada, the U.S., the U.K. and Ireland.
Average Trading Volume: 1,131,774
Technical Sentiment Signal: Sell
Current Market Cap: $1.41M
Find detailed analytics on HELP stock on TipRanks’ Stock Analysis page.